DEK调节B细胞的增殖能力,并与低度B细胞淋巴瘤的侵袭性疾病有关
Melissa A Hopper1, Abigail R Dropik1, Janek S Walker1
1Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Blood cancer journal
|October 9, 2024
概括
瘤蛋白DEK驱动低级B细胞淋巴瘤 (LGBCL) 的生长,并降低了生存率. 向DEK显示了对侵袭性LGBCL的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 瘤蛋白DEK与各种癌症有关.
- 它在低级B细胞淋巴瘤 (LGBCL) 病原发生中的作用尚未完全理解.
研究的目的:
- 调查DEK在LGBCL中的作用.
- 探索DEK作为LGBCL的潜在治疗标和生物标志物.
主要方法:
- 在LGBCL患者样本中分析DEK表达.
- DEK表达与临床结果和遗传变化的相关性.
- 生成DEK淘汰细胞系模型,以研究其功能影响.
- 在DEK耗尽后评估细胞增殖,细胞亡和蛋白质表达的变化.
- 对DEK贫乏细胞中诱导亡的药物敏感性的评估.
主要成果:
- 在LGBCL中,DEK表达与瘤扩散的增加和整体存活率的降低相关.
- DEK表达与LGBCL瘤的拷贝数变化有关.
- DEK 枯竭减少了细胞的增殖,并改变了细胞周期和细胞亡调节者的表达 (Bcl-2,Bcl-xL,p53).
- 缺乏DEK的细胞对venetoclax和staurosporine的敏感性增加.
结论:
- 在LGBCL中,DEK充当coprotein,促进增殖和抑制亡.
- DEK是激进LGBCL的潜在治疗标和生物标志物.
- 对DEK介导的瘤发生的进一步研究可能会导致改善治疗策略.
更多相关视频
07:09Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
7.4K
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.1K
相关概念视频
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
